Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 2/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | DUT | P33316 | 3/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17146870 | 1.00 | GGPS1 (0.53) | GGPS1TBXAS1DUTSLC9A1GPR84 | |
| SCHEMBL10078113 | 1.00 | GGPS1 (0.53) | GGPS1TBXAS1DUTSLC9A1GPR84 | |
| SCHEMBL3546670 | 0.98 | GGPS1 (0.51) | GGPS1TBXAS1DUTSLC9A1GPR84 | |
| SCHEMBL3540514 | 0.96 | GGPS1 (0.53) | GGPS1TBXAS1DUTSLC9A1GPR84 | |
| SCHEMBL21318209 | 0.96 | GGPS1 (0.53) | GGPS1TBXAS1DUTSLC9A1GPR84 | |
| SCHEMBL23619204 | 0.96 | GGPS1 (0.53) | GGPS1TBXAS1DUTSLC9A1GPR84 | |
| SCHEMBL12510483 | 0.96 | GGPS1 (0.53) | GGPS1TBXAS1DUTSLC9A1GPR84 | |
| SCHEMBL18364144 | 0.96 | GGPS1 (0.53) | GGPS1TBXAS1DUTSLC9A1GPR84 | |
| SCHEMBL24975735 | 0.96 | GGPS1 (0.53) | GGPS1TBXAS1DUTSLC9A1GPR84 | |
| SCHEMBL5020918 | 0.96 | GGPS1 (0.53) | GGPS1TBXAS1DUTSLC9A1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369728-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2017218949-A2 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| WO-2017205786-A1 | CELL PERMEABLE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9789164-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790262-B2 | Compositions comprising glucagon analogs and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782454-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20130023646-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20120190818-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | NASH HUW M | 2011-10-13 | — | — | US | disclosed |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | PREP, ANPEP, DNPEP | GGPS1 2366/4885TBXAS1 4278/4885DUT 3685/4885 |
| US-20120190818-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | GGPS1 1017/4885TBXAS1 261/4885DUT 3016/4885 |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | GGPS1 1373/4885TBXAS1 2135/4885DUT 4168/4885 |
| US-20130023646-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | GGPS1 1228/4885TBXAS1 3454/4885DUT 2173/4885 |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | TP53, TP53BP1, VHL | GGPS1 2545/4885TBXAS1 4632/4885DUT 3558/4885 |
| US-20200369728-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | NGLY1, BID, DNPEP | GGPS1 1066/4885TBXAS1 1956/4885DUT 2795/4885 |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | SLC29A2, SLC29A1, SLC22A3 | GGPS1 3084/4885TBXAS1 3202/4885DUT 395/4885 |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | GGPS1 1228/4885TBXAS1 3454/4885DUT 2173/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | GGPS1 1548/4885TBXAS1 3977/4885DUT 3729/4885 |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | GGPS1 2395/4885TBXAS1 3851/4885DUT 3706/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | GGPS1 1248/4885TBXAS1 3153/4885DUT 1429/4885 |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | PCNA, MKI67, NFATC1 | GGPS1 1248/4885TBXAS1 3153/4885DUT 1429/4885 |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | GGPS1 2395/4885TBXAS1 3851/4885DUT 3706/4885 |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | VIP, FLT3, HAVCR2 | GGPS1 1106/4885TBXAS1 2116/4885DUT 4055/4885 |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | GGPS1 1373/4885TBXAS1 2135/4885DUT 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.